This inventor holds 2 USPTO granted patents. Top assignees: National Center for Genetic Engineering & Biotechnology, National Science & Technology Development Agency, Yamanouchi Pharmaceutical Company Ltd.. Active years: 1998-2008.
Company Filing History:
1 out of 1 
1 out of 329 Years Active: 1998-2008
Title: **Masahiko Isaka: Innovator in Antituberculosis Compounds**
Introduction
Masahiko Isaka is a distinguished inventor based in Bangkok, Thailand, known for his significant contributions to the field of pharmaceuticals. With a total of two patents, Isaka's work primarily focuses on the development of innovative compounds that have the potential to combat important health challenges, such as tuberculosis.
Latest Patents
Isaka's latest patents include groundbreaking inventions related to antituberculosis compounds. He has developed a series of three new alkaloids known as Hirsutellones A, B, and C, which are produced in cultures of specific fungal strains, including strain BCC 2594 and sp. strain BCC 7579. These Hirsutellones have demonstrated potent growth inhibitory activity against the H37Ra strain of tuberculosis, with a minimum inhibitory concentration (MIC) value of 0.78 µg/ml. Importantly, these compounds exhibit weak or no cytotoxicity to mammalian cells, suggesting they hold promise for safe pharmaceutical applications. Furthermore, the patents detail methods for isolating these valuable Hirsutellones, paving the way for their potential use in treatments for tuberculosis.
Career Highlights
Throughout his career, Masahiko Isaka has been associated with prominent organizations that contribute to scientific advancement. He has worked with Yamanouchi Pharmaceutical Company Ltd. and the National Center for Genetic Engineering & Biotechnology under the National Science & Technology Development Agency. These experiences have enriched his knowledge and expertise, allowing him to make impactful contributions to medicinal chemistry.
Collaborations
Isaka has collaborated with esteemed colleagues, including Tsukasa Ishihara and Koyo Matsuda, who have played influential roles in his research endeavors. This collaborative environment fosters innovation and pushes the boundaries of current pharmaceutical science.
Conclusion
Masahiko Isaka's inventive work in the realm of antituberculosis compounds stands as a testament to the importance of innovation in addressing global health issues. His patents not only provide valuable insights into the development of new therapeutic options but also highlight the collaborative efforts that drive progress in the scientific community.